Game-changers in the field of genome analysis for pathogens
The ‘golden age’ of antibiotics, kick-started by Fleming’s discovery of penicillin and Florey and his colleagues’ development of penicillin and cephalosporins spanned the 1930s to the 1960s. About half of the drugs we use to fight infection today were discovered in that period. The pace of discovery has fallen since then, and we are losing the arms-race between bacterial innovation in developing resistance and human discovery and invention of new agents.
That is the tip of the iceberg – 100x larger non-resistant bacteria market
Knowing which species of bacteria is not enough, we need scalable joined-up
What is our biggest challenge?
Cost of AMR to reach $100 trillion by 2050
Antimicrobial resistance is the biggest challenge we face as a human race with a global economic cost of over $100 trillion by 2050, and annual-associated deaths that will exceed cancer, according to WHO. Once treatable infections will become increasingly impossible and unaffordable to control, and once safe hospital procedures will become life-threatening.
Bacterial threat beyond the point of control
It is essential that new and emergent bacterial threats can be effectively identified and controlled in hospital settings, as well as in animals, food, and the environment. The COVID-19 / SARS-CoV-2 pandemic highlights how imperative it is that an outbreak is not allowed to grow beyond the point of control. This is exactly the situation we face with AMR.
What is the solution?
Joined-up, genomics-based diagnostics
It is critical that analysis for high-resolution diagnostics is able to distinguish individual challenging strains of bacteria to the diagnostic front-line and that we improve our ability to co-ordinate responses. We need scalable, joined-up, genomics-based diagnostics that can inform infection control and effective responses in real clinical time and to create our own network to enable this.
Latest blogs from GenPAx
Latest blog from GenPAx
Send a message